Control of arterial pressure by angiotensin II and nitric oxide at the onset of diabetes

Michael W Brands, Leslie J. Cloud

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We have reported that the induction of diabetes in Nω-nitro-L-orginine methyl ester (L-NAME)-infused rats causes significant hypertension that is associated with increased plasma renin activity. This study tested the role of angiotensin II (Ang II) by clamping it chronically at baseline levels. The clamp consisted of an intravenous infusion of enalapril (10 mg/kg/d), which decreased mean arterial pressure (MAP) by ∼20 mm Hg after 3 days, and adding chronic Ang II at 4 ng/kg/min, which restored MAP to normal. Chronic L-NAME infusion increased MAP to 127 ± 1 and 132 ± 2 mm Hg in normal and clamped rats, respectively, and induction of diabetes (streptozotocin) increased MAP progressively in normal rats to 161 ± 8 mm Hg by day 12, whereas MAP in the clamped rats decreased progressively to 98 ± 5 mm Hg by day 12. In non-L-NAME rats, MAP averaged 95 ± 1 and 91 ± 1 mm Hg for normal and clamped groups, respectively, before diabetes, and MAP was 10 to 13 mm Hg lower in the clamped versus normal rats midway through the diabetic period. This suggests that Ang II is important for maintaining blood pressure at the onset of diabetes, possibly to compensate for renal volume losses. Angiotensin II also is required for the hypertension caused by induction of diabetes in rats with chronic blockade of nitric oxide synthesis, but whether this is due to increased volume sensitivity in L-NAME-treated, vasoconstricted rats remains to be determined.

Original languageEnglish (US)
Pages (from-to)600-603
Number of pages4
JournalAmerican Journal of Hypertension
Volume16
Issue number7
DOIs
StatePublished - Jul 1 2003

Fingerprint

Angiotensin II
Arterial Pressure
Nitric Oxide
NG-Nitroarginine Methyl Ester
Hypertension
Enalapril
Experimental Diabetes Mellitus
Renin
Intravenous Infusions
Constriction
Esters
Blood Pressure
Kidney

Keywords

  • Diabetes
  • Hypertension
  • Nitric oxide
  • Renin-angiotensin system

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Control of arterial pressure by angiotensin II and nitric oxide at the onset of diabetes. / Brands, Michael W; Cloud, Leslie J.

In: American Journal of Hypertension, Vol. 16, No. 7, 01.07.2003, p. 600-603.

Research output: Contribution to journalArticle

@article{391bd955ad1747a28dfd0e73a03d80f8,
title = "Control of arterial pressure by angiotensin II and nitric oxide at the onset of diabetes",
abstract = "We have reported that the induction of diabetes in Nω-nitro-L-orginine methyl ester (L-NAME)-infused rats causes significant hypertension that is associated with increased plasma renin activity. This study tested the role of angiotensin II (Ang II) by clamping it chronically at baseline levels. The clamp consisted of an intravenous infusion of enalapril (10 mg/kg/d), which decreased mean arterial pressure (MAP) by ∼20 mm Hg after 3 days, and adding chronic Ang II at 4 ng/kg/min, which restored MAP to normal. Chronic L-NAME infusion increased MAP to 127 ± 1 and 132 ± 2 mm Hg in normal and clamped rats, respectively, and induction of diabetes (streptozotocin) increased MAP progressively in normal rats to 161 ± 8 mm Hg by day 12, whereas MAP in the clamped rats decreased progressively to 98 ± 5 mm Hg by day 12. In non-L-NAME rats, MAP averaged 95 ± 1 and 91 ± 1 mm Hg for normal and clamped groups, respectively, before diabetes, and MAP was 10 to 13 mm Hg lower in the clamped versus normal rats midway through the diabetic period. This suggests that Ang II is important for maintaining blood pressure at the onset of diabetes, possibly to compensate for renal volume losses. Angiotensin II also is required for the hypertension caused by induction of diabetes in rats with chronic blockade of nitric oxide synthesis, but whether this is due to increased volume sensitivity in L-NAME-treated, vasoconstricted rats remains to be determined.",
keywords = "Diabetes, Hypertension, Nitric oxide, Renin-angiotensin system",
author = "Brands, {Michael W} and Cloud, {Leslie J.}",
year = "2003",
month = "7",
day = "1",
doi = "10.1016/S0895-7061(03)00902-6",
language = "English (US)",
volume = "16",
pages = "600--603",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Control of arterial pressure by angiotensin II and nitric oxide at the onset of diabetes

AU - Brands, Michael W

AU - Cloud, Leslie J.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - We have reported that the induction of diabetes in Nω-nitro-L-orginine methyl ester (L-NAME)-infused rats causes significant hypertension that is associated with increased plasma renin activity. This study tested the role of angiotensin II (Ang II) by clamping it chronically at baseline levels. The clamp consisted of an intravenous infusion of enalapril (10 mg/kg/d), which decreased mean arterial pressure (MAP) by ∼20 mm Hg after 3 days, and adding chronic Ang II at 4 ng/kg/min, which restored MAP to normal. Chronic L-NAME infusion increased MAP to 127 ± 1 and 132 ± 2 mm Hg in normal and clamped rats, respectively, and induction of diabetes (streptozotocin) increased MAP progressively in normal rats to 161 ± 8 mm Hg by day 12, whereas MAP in the clamped rats decreased progressively to 98 ± 5 mm Hg by day 12. In non-L-NAME rats, MAP averaged 95 ± 1 and 91 ± 1 mm Hg for normal and clamped groups, respectively, before diabetes, and MAP was 10 to 13 mm Hg lower in the clamped versus normal rats midway through the diabetic period. This suggests that Ang II is important for maintaining blood pressure at the onset of diabetes, possibly to compensate for renal volume losses. Angiotensin II also is required for the hypertension caused by induction of diabetes in rats with chronic blockade of nitric oxide synthesis, but whether this is due to increased volume sensitivity in L-NAME-treated, vasoconstricted rats remains to be determined.

AB - We have reported that the induction of diabetes in Nω-nitro-L-orginine methyl ester (L-NAME)-infused rats causes significant hypertension that is associated with increased plasma renin activity. This study tested the role of angiotensin II (Ang II) by clamping it chronically at baseline levels. The clamp consisted of an intravenous infusion of enalapril (10 mg/kg/d), which decreased mean arterial pressure (MAP) by ∼20 mm Hg after 3 days, and adding chronic Ang II at 4 ng/kg/min, which restored MAP to normal. Chronic L-NAME infusion increased MAP to 127 ± 1 and 132 ± 2 mm Hg in normal and clamped rats, respectively, and induction of diabetes (streptozotocin) increased MAP progressively in normal rats to 161 ± 8 mm Hg by day 12, whereas MAP in the clamped rats decreased progressively to 98 ± 5 mm Hg by day 12. In non-L-NAME rats, MAP averaged 95 ± 1 and 91 ± 1 mm Hg for normal and clamped groups, respectively, before diabetes, and MAP was 10 to 13 mm Hg lower in the clamped versus normal rats midway through the diabetic period. This suggests that Ang II is important for maintaining blood pressure at the onset of diabetes, possibly to compensate for renal volume losses. Angiotensin II also is required for the hypertension caused by induction of diabetes in rats with chronic blockade of nitric oxide synthesis, but whether this is due to increased volume sensitivity in L-NAME-treated, vasoconstricted rats remains to be determined.

KW - Diabetes

KW - Hypertension

KW - Nitric oxide

KW - Renin-angiotensin system

UR - http://www.scopus.com/inward/record.url?scp=0037560301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037560301&partnerID=8YFLogxK

U2 - 10.1016/S0895-7061(03)00902-6

DO - 10.1016/S0895-7061(03)00902-6

M3 - Article

C2 - 12850396

AN - SCOPUS:0037560301

VL - 16

SP - 600

EP - 603

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 7

ER -